Resmed (RMD.ASX) reports first quarter FY17 results on the 26th of October. The result is likely to meet or exceed market expectations.
RMD is forecast to deliver 10%+ in EPS growth across the next few years. The recent acquisition of Brightree, Inova and Curative Medical will underpin both revenue and future profit growth, within an industry sector where demand continues to grow.
You're not a member! Trial today
Alex says:
Hello Leon,
Is your advice “get ready” to buy or ” buy” today?
Alex Livshiz
Leon says:
Hi,
RMD hit our target buy range. With company earnings out at the end of the month and the stock pulling back to around $8.50, risk/reward makes sense to be set before the result.